Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma.

M. M. Walther, S. B. Jennings, P. L. Choyke, M. Andrich, K. Hurley, W. M. Linehan, S. A. Rosenberg, R. B. Alexander

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Patients with localized renal-cell carcinoma who are candidates for renal parenchymal sparing surgery are being treated with isolated renal perfusion with recombinant human tumor necrosis factor (TNF). Isolated organ perfusion is a surgical technique that allows a cancer-bearing organ or region of the body to be treated with high doses of chemotherapy or biologic, agents that would not be tolerated systemically. In patients with in-transit melanoma or unresectable sarcoma, treatment with hyperthermic isolated limb perfusion using TNF, interferon-gamma, and melphalan has resulted in response rates exceeding 90%. Because preclinical studies suggest that TNF may induce regression of tumors by causing hemorrhagic necrosis mediated by effects on tumor-related vascular endothelium, a vascular tumor such as renal-cell carcinoma could potentially be very responsive. A phase I study of escalating TNF doses delivered via isolated renal perfusion is currently being conducted.

Original languageEnglish (US)
Pages (from-to)S2-7
JournalWorld journal of urology
Volume14 Suppl 1
StatePublished - 1996
Externally publishedYes

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma.'. Together they form a unique fingerprint.

Cite this